Search Blog
Categories
October 2018
M T W T F S S
1234567
891011121314
15161718192021
22232425262728
293031  

Tags

EastWest Bioscience Pushes Boundaries to Expand into Cannabis and CBD

FSCWIRE

EastWest Bioscience Pushes Boundaries to Expand into Cannabis and CBD

Company engages cannabis expert to expand into CBD with application to Health Canada for Dealer’s Licence.

Vancouver, British Columbia (FSCwire) – Harbour Star Capital Corp. dba EastWest Bioscience (the “Company” or “EastWest”) (TSX.V: EAST) announces it has engaged Phytosciences Consulting LLC. (“Phytosciences”), a US-based consulting firm with an array of cannabis expertise ranging from laboratory design, specification, and setup to pharmaceutical product design, testing, and manufacturing.

Phytosciences provides quality control and quality assurance services to the medical cannabis industry. Phytoscience’s management team consists of experienced cannabis research scientists and extraction specialists. Guided by sound and well-designed clinical research, Phytoscience is focused on developing standardized cannabis-based therapeutics and has been instrumental in developing many of the established standards within the cannabis laboratory testing and product development sector, becoming a global leader in Good Laboratory and Testing Practices for cannabis. Phytoscience clients’ can be confident the products they develop are designed and manufactured to the highest pharmacological standards.

This engagement of Phytosciences as consultant to EastWest will support EastWest’s ambitious strategy to expand its cannabis operations beyond industrial hemp and hemp food products into the medical marijuana and CBD markets. This will open up new business opportunities with the development of profitable new cannabis products. To that end, the Company has begun its application to the Office of Controlled Substances within Health Canada for a cannabis Dealer’s Licence. This will allow the Company to conduct trade of fresh and dried marijuana, cannabis oils, and concentrates, formulate research and development of cannabis products, and orchestrate analytical testing.

The acquisition of a Dealer Licence will enable EastWest to begin cultivating, extracting, testing, importing, exporting, and producing medical cannabis products including concentrated oil and resin products. The Company intends to produce and market these highly profitable products both domestically and internationally. Attaining its Dealer’s Licence advances the Company’s unique seed-to-shelf strategy and is another major step towards the Company’s 360 Market Vision. This mid-term vision includes acquisition and control of both its supply chain and its’ distribution chain and what the Company believes will be its real competitive market advantage. To that effect, the Company will also be announcing in the near future major acquisitions that will literally bake-in its own sales distribution, a major market strategy unique to EastWest.

ON BEHALF OF THE BOARD OF DIRECTORS

EASTWEST BIOSCIENCE GROUP

“Rodney Gelineau”

Co-Founder, Chief Executive Officer and Director

For further information, please visit www.eastwestbioscience.com or contact EastWest Bioscience representatives at 1-800-409-1930 or investors@eastwestscience.com.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER TO SELL SECURITIES OR A SOLICITATION FOR PURCHASERS TO BUY SECURITIES AND IS BEING ISSUED TO COMPLY WITH REGULATORY REQUIREMENTS. THIS PRESS RELEASE IS NOT TO BE CONSTRUED AS A PUBLIC OFFERING IN ANY PROVINCE IN CANADA UNLESS A PROSPECTUS RELATING THERETO HAS BEEN ACCEPTED FOR FILING BY A SECURITIES COMMISSION OR SIMILAR AUTHORITY IN SUCH PROVINCE.

To view the original release (with media), please click

Maximum News Dissemination by FSCwire. https://www.fscwire.com

Copyright © 2018 FSCwire